Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6759244

Title:Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
Inventors:Alikani, Mina; New York, NY, USA
Willadsen, Steen Malte; Windermere, FL, USA
Summary:This invention discloses a preparation and a method of making composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos. The CB is characterized morphologically by having two distinct tissue types, the inner cell mass (ICM) and the trophectoderm (TE), and a blastocoelic cavity (BC). The method of making CBs is an aggregation process (AP) comprising the dissociation of discarded pre-embryos, the isolation of single nucleated cells from dissociated discarded pre-embryos, the microsurgical encapsulation of several cells within a host zona pellucida or artificial aggregation with or without a non-zona vessel, and a primary culture of the cell aggregates for multiplication and differentiation of cells. Further advantages from using starting material that consists of non-viable pre-embryos, as well as the processes of novel aggregation from the CBs, are further disclosed.
Abstract:A preparation and a method of making composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos are disclosed. The CB is characterized morphologically by having two distinct tissue types, the inner cell mass (ICM) and the trophectoderm (TE), and a blastocoelic cavity (BC). The method of making CBs is an aggregation process (AP) comprising inter alia the following steps: 1) dissociation of discarded pre-embryos; 2) isolation of single nucleated cells from dissociated discarded pre-embryos; 3) microsurgical encapsulation of several cells within a host zona pellucida or artificial aggregation with or without a non-zona vessel; and 5) primary culture of the cell aggregates for multiplication and differentiation of cells. One particularly advantageous embodiment is that the starting material is non-viable pre-embryos. Another advantageous embodiment is that the AP allows individual cells from non-viable pre-embryos to further multiply, and become integrated into CBs. The novel CBs and the novel aggregation process disclosed. One particularly advantageous embodiment is that the starting material is non-viable pre-embryos. Another advantageous embodiment is that the AP allows individual cells from non-viable pre-embryos to further multiply, and become integrated into CBs. The novel CBs and the novel aggregation process are disclosed.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6759244
Application Number:US2001000036581
Date Filed:08/11/2001
Date Published:06/07/2004
Assignee:Art Institute of New York and New Jersey, Inc., New York, NY, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021